Business
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters.
About this update from Becton, Dickinson And Company
[{"type":"text","content":"Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction","length":190,"tagName":"p","attribs":{}},{"type":"text","content":"MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters.","length":538,"tagName":"p"},{"type":"image","alt":"Waters Corporation","displaySize":"","headline":null,"caption":"Waters Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":101,"url":"https://media.zenfs.com/en/prnewswire.com/db396cbf3228fd9e6e853d036e380f8a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WQqjrfH5XUxveu8U5WgKbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/db396cbf3228fd9e6e853d036e380f8a","width":400,"height":101}},"href":"https://mma.prnewswire.com/media/2870143/Waters_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We appreciate the continued support of our shareholders as we move closer to completing this transaction," said Udit Batra, Ph.D., President and Chief Executive Officer, Waters Corporation. "With this milestone complete, our focus is on closing the transaction and ushering in the next chapter of growth and innovation as a differentiated leader in life sciences and diagnostics. We look forward to creating meaningful value for patients, customers, employees, and shareholders alike."","length":506,"tagName":"p"},{"type":"text","content":"BD has received a favorable Private Letter Ruling from the Internal Revenue Service regarding matters relating to the U.S. federal income tax consequences of the transaction. Waters and BD have also received all of the required regulatory approvals. The transaction is expected to close on February 9, 2026, subject to the satisfacti...